Physician

Puvanalingam Ayyadurai, MD

According to 2025 Medicare claims, Puvanalingam Ayyadurai, MD (NPI: 1972919942) practices cardiology in the Grand Forks, ND-MN market, with the plurality of this provider's patient population coming from Grand Forks, ND. This provider's primary affiliated billing organization is ALTRU HEALTH SYSTEM (NPI: 1043309552; TIN: 450310462) and primary practice location at 58201-4012. Ayyadurai is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Caravan Health ACO 50 LLC (ACO ID: A5160), CVS ACO (ACO ID: A5407), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Ayyadurai's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,247 traditional Medicare patients, billed 5,809 HCPCS/CPT codes, and received $171,594 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 3,445 prescription claims across 505 beneficiaries totaling $3,341,758 in drug costs, led by Vyndamax (Tafamidis). DME data shows 26 claims. Open Payments data shows 11 records totaling $40,550. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $20,700 to $3,341,758. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	1,387	2,917	$89,357
2021	2,878	7,565	$216,421
2022	2,570	6,318	$178,523
2023	2,328	6,334	$171,152
2024	2,247	5,809	$171,594

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	346	$20,700
2016	42	256	$13,660
2017	50	309	$14,972
2018	42	280	$8,983
2019	74	761	$28,743
2020	138	944	$46,143
2021	302	1,621	$148,514
2022	414	2,331	$999,126
2023	457	3,241	$1,835,286
2024	505	3,445	$3,341,758

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	14	$224,288
2024	N/R	26	$212,992

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	237	312	$105
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	859	875	$52
93018	Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician	235	237	$10
93793	Anticoagulant management of patient taking warfarin	472	2,312	$8
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	520	595	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	56	1,680	$1,191,643
Tyvaso Dpi	Treprostinil	16	448	$379,306
Opsumit	Macitentan	38	1,116	$369,183
Winrevair	Sotatercept-Csrk	11	231	$298,364
Orenitram Er	Treprostinil Diolamine	63	1,642	$262,229

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7686	Treprostinil, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, 1.74 mg	N	N/R	13	$212,656
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	13	$336

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$604	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$39,947	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Puvanalingam Ayyadurai, MD?

Tedicare shows public-source Medicare data for Puvanalingam Ayyadurai, MD (NPI 1972919942), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Puvanalingam Ayyadurai, MD have ACO affiliation data?

Puvanalingam Ayyadurai, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Caravan Health ACO 50 LLC (MSSP, ACO ID A5160), CVS ACO (MSSP, ACO ID A5407), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Puvanalingam Ayyadurai, MD?

Puvanalingam Ayyadurai, MD is linked to ALTRU HEALTH SYSTEM (billing NPI 1043309552) in the available physician profile data.

Does Puvanalingam Ayyadurai, MD have Open Payments data?

Puvanalingam Ayyadurai, MD has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.